Psychedelic ingredient psilocybin, also known as “magic mushrooms Canada,” has been shown in a new research to increase brain connectivity. The findings were published on Monday in the journal. In the past, the hallucinogenic substance psilocybin was shown to have antidepressant benefits, and this discovery explains why.
It performs better and lasts longer.
There are about 200 species of psilocybin mushrooms that contain the naturally occurring chemical psilocybin. In addition to altering one’s viewpoint, hallucinations, and euphoria, the effects may last for up to six hours.
Shroom mushrooms, as they are often known, are absolutely safe to eat in moderation and with knowledge on how to distinguish them from other mushrooms that may appear similar but are really detrimental to the consumer. They do not seem to be addictive.
Some people, however, have reported experiencing “bad trips” or panic attacks after ingesting them.
Psilocybin, despite this, seems to have good antidepressant effects. [Reference required] [Reference required]
It seems that psilocybin’s positive effects begin to take hold far more rapidly than traditional antidepressants, which often take several weeks to begin to have an impact. Psilocybin seems to have longer-lasting effects as well. Discovering the mechanisms at work has been made a little easier with the publication of this new study.
The brain’s cells form more connections with each other.
The functional magnetic resonance imaging data of depressed patients who had participated in two independent clinical trials in the past that had employed psilocybin therapy was evaluated in a study published on Monday. fMRI scans the brain in order to see which parts are active and which aren’t, and it does so through a computer screen.
Individuals with depression who received psilocybin therapy had brain regions that seemed more connected than they were before getting treatment, according to the study. According to this new data, the brain’s formerly separate areas have become more interconnected after enduring this shift.
Connectivity between areas of the human brain is like the transportation system of a vast metropolis. In those who are sad, several parts of the brain seem to have an excessively large number of isolated connections. The microdosing psilocybin is Similar to a residential neighbourhood being overrun by traffic. As a result, traffic is limited to a relatively small area, as if there were no roads connecting the neighbourhoods in issue to the rest of the city.
When these people took psilocybin, their mental city traffic started flowing between neighbourhoods and dispersed across the city brain, according to researchers.
Three-dimensional representation of brain cells
There may be an increase in flexibility and emotional calm as a result of the improved functional relationship. MindMed, a New York-based psychedelic medicine company, has hired Liechti as a consultant, and it’s worth noting.
There is still a long and strange road ahead.
In order to understand why psilocybin may be therapeutic to those who suffer from depression, this study is critical. Despite the fact that the exact mechanism through which psilocybin operates is still a mystery, this research is significant nevertheless. Psilocybin’s antidepressant benefits, according to Harris’s research, are the result of a “global increase in brain network integration,” according to Carhart. It is commonly believed that psilocybin mushrooms “rewire your brain,” and this data supports that idea. Psilocybin mushrooms “rewire your brain,” according to common belief, may really be true.
Even while LSD and ayahuasca are well-known for their ability to alleviate sadness, the therapeutic effects of LSD and other psychedelics are not limited to this condition. As well, they’ve showed promising results in the treatment of OCD, as well as a variety of chemical addictions, including nicotine and alcoholism.
A phase 2 research in Germany is now looking at the effects of psilocybin vs a placebo to see which is more effective. One hundred forty-four people with treatment-resistant severe depression are being recruited to participate in the trial. However, psilocybin’s benefits, safety, and efficacy in the treatment of depression and other mental ailments seem promising, but the evidence that is now accessible is still based on a limited number of clinical investigations.